Just how flexible does a Big Pharma have to be to win an important new drug? Practically contortionary.
Vertex Pharmaceuticals Inc. 's deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950...
Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.
Just how flexible does a Big Pharma have to be to win an important new drug? Practically contortionary.
Vertex Pharmaceuticals Inc. 's deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950...
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.
The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.